NCT00610051View on ClinicalTrials.gov

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2026

Conditions
Heart Failure
Interventions
DRUG

Alprostadil

central venous access continuous delivery with 500mcg/48 hours in active arm

Trial Locations (1)

Unknown

Medical university Vienna, Vienna

Sponsors
All Listed Sponsors
lead

Biopeutics Co., Ltd

INDUSTRY